{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:04:21Z","timestamp":1794013461447,"version":"4.8.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1212\/01.con.0000466662.89908.e7","type":"journal-article","created":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T13:25:41Z","timestamp":1433424341000},"page":"715-736","source":"Crossref","is-referenced-by-count":173,"title":["Psychosis"],"prefix":"10.1212","volume":"21","author":[{"given":"David B.","family":"Arciniegas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","unstructured":"Morgan C Lappin J Heslin M et al. Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study. Psychol Med 2014; 44 (13): 2713\u20132726. doi:10.1017\/S0033291714000282.","DOI":"10.1017\/S0033291714000282"},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","unstructured":"Rabinowitz J Berardo CG Bugarski-Kirola D Marder S. Association of prominent positive and prominent negative symptoms and functional health well-being healthcare-related quality of life and family burden: a CATIE analysis. Schizophr Res 2013; 150 (2\u20133): 339\u2013342. doi:10.1016\/j.schres.2013.07.014.","DOI":"10.1016\/j.schres.2013.07.014"},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","unstructured":"Vilalta-Franch J Lopez-Pousa S Calvo-Perxas L Garre-Olmo J. Psychosis of Alzheimer disease: prevalence incidence persistence risk factors and mortality. Am J Geriatr Psychiatry 2013; 21 (11): 1135\u20131143. doi:10.1016\/j.jagp.2013.01.051.","DOI":"10.1016\/j.jagp.2013.01.051"},{"key":"e_1_3_1_5_2","doi-asserted-by":"crossref","unstructured":"Forsaa EB Larsen JP Wentzel-Larsen T et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 2010; 67 (8): 996\u20131001. doi:10.1001\/archneurol.2010.166.","DOI":"10.1001\/archneurol.2010.166"},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association DSM-5 Task Force. Diagnostic and statistical manual of mental disorders 5th Edition (DSM-5). Washington DC: American Psychiatric Association 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_1_7_2","unstructured":"American Psychiatric Association Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders 4th edition text revision (DSM-IV-TR). Washington DC: American Psychiatric Association 2000."},{"key":"e_1_3_1_8_2","unstructured":"American Psychiatric Association Committee on Nomenclature and Statistics. Diagnostic and statistical manual of mental disorders 2nd edition (DSM-II). Arlington: American Psychiatric Association 1968."},{"key":"e_1_3_1_9_2","unstructured":"World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization 1992."},{"key":"e_1_3_1_10_2","unstructured":"Schneider K. Clinical psychopathology. New York: Grune & Stratton 1959."},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","unstructured":"Arciniegas DB. Mental status examination. In: Arciniegas DB Anderson CA Filley CM eds. Behavioral Neurology and Neuropsychiatry. Cambridge England: Cambridge University Press; 2013: 344\u2013393.","DOI":"10.1017\/CBO9781139016919.025"},{"key":"e_1_3_1_12_2","unstructured":"Bonhoeffer K. Die akuten Geisteskrankheiten der Gewohnheitstrinker. Jena: G. Fischer 1901."},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","unstructured":"Edelstyn NM Oyebode F. A review of the phenomenology and cognitive neuropsychological origins of the Capgras syndrome. Int J Geriatr Psychiatry 1999; 14 (1): 48\u201359. doi:10.1002\/(SICI)1099-1166(199901)14:1<48::AID-GPS891>3.0.CO;2-0.","DOI":"10.1002\/(SICI)1099-1166(199901)14:1<48::AID-GPS891>3.3.CO;2-S"},{"key":"e_1_3_1_14_2","doi-asserted-by":"crossref","unstructured":"Christodoulou GN Margariti M Kontaxakis VP Christodoulou NG. The delusional misidentification syndromes: strange fascinating and instructive. Curr Psychiatry Rep 2009; 11 (3): 185\u2013189. doi:10.1007\/s11920-009-0029-6.","DOI":"10.1007\/s11920-009-0029-6"},{"key":"e_1_3_1_15_2","doi-asserted-by":"crossref","unstructured":"Arnedo J Svrakic DM Del Val C et al. Uncovering the hidden risk architecture of the schizophrenias: confirmation in three independent genome-wide association studies. Am J Psychiatry 2014. doi:10.1176\/appi.ajp.2014.14040435. [Epub ahead of print].","DOI":"10.1176\/appi.ajp.2014.14040435"},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","unstructured":"Linscott RJ van Os J. An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: on the pathway from proneness to persistence to dimensional expression across mental disorders. Psychol Med 2013; 43 (6): 1133\u20131149. doi:10.1017\/S0033291712001626.","DOI":"10.1017\/S0033291712001626"},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","unstructured":"Morgan VA Valuri GM Croft ML et al. Cohort profile: pathways of risk from conception to disease: the Western Australian schizophrenia high-risk e-Cohort. Int J Epidemiol 2011; 40 (6): 1477\u20131485. doi:10.1093\/ije\/dyq167.","DOI":"10.1093\/ije\/dyq167"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","unstructured":"Insel T Cuthbert B Garvey M et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010; 167 (7): 748\u2013751. doi:10.1176\/appi.ajp.2010.09091379.","DOI":"10.1176\/appi.ajp.2010.09091379"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","unstructured":"Ford JM Morris SE Hoffman RE et al. Studying hallucinations within the NIMH RDoC framework. Schizophr Bull 2014; 40 (suppl 4): S295\u2013S304. doi:10.1093\/schbul\/sbu011.","DOI":"10.1093\/schbul\/sbu011"},{"key":"e_1_3_1_20_2","unstructured":"Clinician-rated dimensions of psychosis symptom severity. American Psychiatric Association. www.psychiatry.org\/File%20Library\/Practice\/DSM\/DSM-5\/ClinicianRatedDimensionsOfPsychosisSymptomSeverity.pdf. Published 2013. Accessed April 9 2015."},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","unstructured":"Chemerinski E Triebwasser J Roussos P Siever LJ. Schizotypal personality disorder. J Pers Disord 2013; 27 (5): 652\u2013679. doi:10.1521\/pedi_2012_26_053.","DOI":"10.1521\/pedi_2012_26_053"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","unstructured":"Saddichha S Kumar R Sur S Sinha BN. First rank symptoms: concepts and diagnostic utility. Afr J Psychiatry (Johannesbg) 2010; 13 (4): 263\u2013266. doi:10.4314\/ajpsy.v13i4.61874.","DOI":"10.4314\/ajpsy.v13i4.61874"},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","unstructured":"Tandon R Gaebel W Barch DM et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res 2013; 150 (1): 3\u201310. doi:10.1016\/j.schres.2013.05.028.","DOI":"10.1016\/j.schres.2013.05.028"},{"key":"e_1_3_1_24_2","doi-asserted-by":"crossref","unstructured":"Braff DL Ryan J Rissling AJ Carpenter WT. Lack of use in the literature from the last 20 years supports dropping traditional schizophrenia subtypes from DSM-5 and ICD-11. Schizophr Bull 2013; 39 (4): 751\u2013753. doi:10.1093\/schbul\/sbt068.","DOI":"10.1093\/schbul\/sbt068"},{"key":"e_1_3_1_26_2","doi-asserted-by":"crossref","unstructured":"McAllister TW Arciniegas DB. Pharmacotherapy of behavioral disturbances. In: Arciniegas DB Anderson CA Filley CM eds. Behavioral Neurology and Neuropsychiatry. Cambridge England: Cambridge University Press; 2013: 566\u2013586.","DOI":"10.1017\/CBO9781139016919.037"},{"key":"e_1_3_1_28_2","unstructured":"Lehman AF Lieberman JA Dixon LB et al. Practice guideline for the treatment of patients with schizophrenia 2nd ed. Arlington: American Psychiatric Association 2004."},{"key":"e_1_3_1_29_2","unstructured":"Clinical practice guidelines. American Psychiatric Association. www.psychiatry.org\/practice\/clinical-practice-guidelines. Accessed April 9 2015."},{"key":"e_1_3_1_30_2","unstructured":"Clinical practice guidelines. American Academy of Neurology. www.aan.com\/Guidelines. Accessed April 9 2015."},{"key":"e_1_3_1_31_2","unstructured":"Guidelines. Scottish Intercollegiate Guidelines Network. www.sign.ac.uk\/guidelines\/index.html. Accessed April 9 2015."},{"key":"e_1_3_1_32_2","unstructured":"National Guideline Clearinghouse. Agency for Healthcare Research and Quality. www.guideline.gov. Accessed April 9 2015."},{"key":"e_1_3_1_33_2","doi-asserted-by":"crossref","unstructured":"Stahl SM Morrissette DA Citrome L et al. \u201cMeta-guidelines\u201d for the management of patients with schizophrenia. CNS Spectr 2013; 18 (3): 150\u2013162. doi:10.1017\/S109285291300014X.","DOI":"10.1017\/S109285291300014X"},{"key":"e_1_3_1_34_2","doi-asserted-by":"crossref","unstructured":"Hasan A Falkai P Wobrock T et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012; 13 (5): 318\u2013378. doi:10.3109\/15622975.2012.696143.","DOI":"10.3109\/15622975.2012.696143"},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","unstructured":"Hasan A Falkai P Wobrock T et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013; 14 (1): 2\u201344. doi:10.3109\/15622975.2012.739708.","DOI":"10.3109\/15622975.2012.739708"},{"key":"e_1_3_1_38_2","doi-asserted-by":"crossref","unstructured":"Cummings JL Mega M Gray K et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44 (12): 2308\u20132314. doi:10.1212\/WNL.44.12.2308.","DOI":"10.1212\/WNL.44.12.2308"},{"key":"e_1_3_1_39_2","doi-asserted-by":"crossref","unstructured":"Leucht S Cipriani A Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382 (9896): 951\u2013962. doi:10.1016\/S0140-6736(13)60733-3.","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"e_1_3_1_41_2","doi-asserted-by":"crossref","unstructured":"Saunders KE Hawton K. The role of psychopharmacology in suicide prevention. Epidemiol Psichiatr Soc 2009; 18 (3): 172\u2013178. doi:10.1017\/S1121189X00000427.","DOI":"10.1017\/S1121189X00000427"},{"key":"e_1_3_1_42_2","doi-asserted-by":"crossref","unstructured":"Desamericq G Schurhoff F Meary A et al. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol 2014; 70 (2): 127\u2013134. doi:10.1007\/s00228-013-1600-y.","DOI":"10.1007\/s00228-013-1600-y"},{"key":"e_1_3_1_43_2","doi-asserted-by":"crossref","unstructured":"Fervaha G Agid O Takeuchi H et al. Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study. Eur Neuropsychopharmacol 2014; 24 (7): 1078\u20131085. doi:10.1016\/j.euroneuro.2014.03.001.","DOI":"10.1016\/j.euroneuro.2014.03.001"},{"key":"e_1_3_1_44_2","doi-asserted-by":"crossref","unstructured":"Percudani M Barbui C Tansella M. Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective. Pharmacoeconomics 2004; 22 (11): 701\u2013718. doi:10.2165\/00019053-200422110-00002.","DOI":"10.2165\/00019053-200422110-00002"},{"key":"e_1_3_1_45_2","doi-asserted-by":"crossref","unstructured":"Slotema CW Blom JD van Lutterveld R et al. Review of the efficacy of transcranial magnetic stimulation for auditory verbal hallucinations. Biol Psychiatry 2014; 76 (2): 101\u2013110. doi:10.1016\/j.biopsych.2013.09.038.","DOI":"10.1016\/j.biopsych.2013.09.038"},{"key":"e_1_3_1_46_2","doi-asserted-by":"crossref","unstructured":"Slotema CW Blom JD Hoek HW Sommer IE. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry 2010; 71 (7): 873\u2013884. doi:10.4088\/JCP.08m04872gre.","DOI":"10.4088\/JCP.08m04872gre"},{"key":"e_1_3_1_47_2","doi-asserted-by":"crossref","unstructured":"Pinto T Lanctot KL Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer\u2019s type. Ageing Res Rev 2011; 10 (4): 404\u2013412. doi:10.1016\/j.arr.2011.01.003.","DOI":"10.1016\/j.arr.2011.01.003"},{"key":"e_1_3_1_48_2","doi-asserted-by":"crossref","unstructured":"Wood LD Neumiller JJ Setter SM Dobbins EK. Clinical review of treatment options for select nonmotor symptoms of Parkinson\u2019s disease. Am J Geriatr Pharmacother 2010; 8 (4): 294\u2013315. doi:10.1016\/j.amjopharm.2010.08.002.","DOI":"10.1016\/j.amjopharm.2010.08.002"},{"key":"e_1_3_1_49_2","doi-asserted-by":"crossref","unstructured":"Ballard C Aarsland D Francis P Corbett A. Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology clinical features and pharmacological management. Drugs Aging 2013; 30 (8): 603\u2013611. doi:10.1007\/s40266-013-0092-x.","DOI":"10.1007\/s40266-013-0092-x"},{"key":"e_1_3_1_50_2","doi-asserted-by":"crossref","unstructured":"Singh J Kour K Jayaram MB. Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database Syst Rev 2012; 1: CD007967. doi:10.1002\/14651858.CD007967.pub2.","DOI":"10.1002\/14651858.CD007967.pub2"},{"key":"e_1_3_1_51_2","doi-asserted-by":"crossref","unstructured":"Sultzer DL Davis SM Tariot PN et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer\u2019s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008; 165 (7): 844\u2013854. doi:10.1176\/appi.ajp.2008.07111779.","DOI":"10.1176\/appi.ajp.2008.07111779"},{"key":"e_1_3_1_52_2","doi-asserted-by":"crossref","unstructured":"Gentile S. Second-generation antipsychotics in dementia: beyond safety concerns. A clinical systematic review of efficacy data from randomised controlled trials. Psychopharmacology (Berl) 2010; 212 (2): 119\u2013129. doi:10.1007\/s00213-010-1939-z.","DOI":"10.1007\/s00213-010-1939-z"},{"key":"e_1_3_1_54_2","doi-asserted-by":"crossref","unstructured":"Ballard C Creese B Corbett A Aarsland D. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf 2011; 10 (1): 35\u201343. doi:10.1517\/14740338.2010.506711.","DOI":"10.1517\/14740338.2010.506711"},{"key":"e_1_3_1_55_2","doi-asserted-by":"crossref","unstructured":"Mittal V Kurup L Williamson D et al. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am J Alzheimers Dis Other Demen 2011; 26 (1): 10\u201328. doi:10.1177\/1533317510390351.","DOI":"10.1177\/1533317510390351"},{"key":"e_1_3_1_56_2","doi-asserted-by":"crossref","unstructured":"Zheng L Mack WJ Dagerman KS et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer\u2019s disease patients: the CATIE-AD study. Am J Psychiatry 2009; 166 (5): 583\u2013590. doi:10.1176\/appi.ajp.2008.08081218.","DOI":"10.1176\/appi.ajp.2008.08081218"},{"key":"e_1_3_1_58_2","unstructured":"Information for Healthcare Professionals: Conventional Antipsychotics. US Food and Drug Administration. www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124830.htm. Accessed April 14 2015."},{"key":"e_1_3_1_59_2","doi-asserted-by":"crossref","unstructured":"Herrmann N Gauthier S. Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMAJ 2008; 179 (12): 1279\u20131287. doi:10.1503\/cmaj.070804.","DOI":"10.1503\/cmaj.070804"}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00132979-201506000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T14:02:45Z","timestamp":1752156165000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/01.CON.0000466662.89908.e7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1212\/01.CON.0000466662.89908.e7"],"URL":"https:\/\/doi.org\/10.1212\/01.con.0000466662.89908.e7","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}